These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16778711)

  • 41. Exacerbation of obsessive-compulsive symptoms associated with clozapine.
    Eales MJ; Layeni AO
    Br J Psychiatry; 1994 May; 164(5):687-8. PubMed ID: 7921724
    [No Abstract]   [Full Text] [Related]  

  • 42. Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia.
    Zink M; Knopf U; Kuwilsky A
    Aust N Z J Psychiatry; 2007 Mar; 41(3):293-4. PubMed ID: 17464712
    [No Abstract]   [Full Text] [Related]  

  • 43. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions.
    Tan MSA; Honarparvar F; Falconer JR; Parekh HS; Pandey P; Siskind DJ
    Psychopharmacology (Berl); 2021 Mar; 238(3):615-637. PubMed ID: 33410989
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia.
    Xiang YQ; Zhang ZJ; Weng YZ; Zhai YM; Li WB; Cai ZJ; Tan QR; Wang CY
    Schizophr Res; 2006 Apr; 83(2-3):201-10. PubMed ID: 16524698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration.
    Yusufi B; Mukherjee S; Flanagan R; Paton C; Dunn G; Page E; Barnes TR
    Int Clin Psychopharmacol; 2007 Jul; 22(4):238-43. PubMed ID: 17519648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induced Obsessive Compulsive Symptoms (OCS) in schizophrenia patients under Atypical 2 Antipsychotics (AAPs): review and hypotheses.
    Grillault Laroche D; Gaillard A
    Psychiatry Res; 2016 Dec; 246():119-128. PubMed ID: 27690134
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients.
    Wong JO; Leung SP; Mak T; Ng RM; Chan KT; Hon-Kee Cheung H; Choi WK; Lai J; Wai-Kiu Tsang A
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):251-64. PubMed ID: 16316716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients.
    Mauri M; Volonteri LS; Fiorentini A; Invernizzi G; Nerini T; Baldi M; Bareggi SR
    Schizophr Res; 2004 Feb; 66(2-3):197-8. PubMed ID: 15061256
    [No Abstract]   [Full Text] [Related]  

  • 49. Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia.
    Fernandez-Egea E; Worbe Y; Bernardo M; Robbins TW
    Psychol Med; 2018 Dec; 48(16):2668-2675. PubMed ID: 29455687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A brief history of clozapine use in Taiwan.
    Lin SK; Lane HY
    Schizophr Res; 2024 Jun; 268():34-37. PubMed ID: 37391310
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aripiprazole augmentation in clozapine-associated obsessive-compulsive symptoms.
    Villari V; Frieri T; Fagiolini A
    J Clin Psychopharmacol; 2011 Jun; 31(3):375-6. PubMed ID: 21532362
    [No Abstract]   [Full Text] [Related]  

  • 52. [Clozapine-induced obsessive-compulsive disorder: a case report].
    Sánchez Bonome L; Barjau Romero JM; Lara Muñoz Rd; Márquez Tejero MC
    Actas Esp Psiquiatr; 2002; 30(5):330-4. PubMed ID: 12372230
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia.
    Hummer M; Kemmler G; Kurz M; Kurzthaler I; Oberbauer H; Fleischhacker WW
    Am J Psychiatry; 1999 Apr; 156(4):631-3. PubMed ID: 10200746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients.
    Poyurovsky M; Hermesh H; Weizman A
    Clin Neuropharmacol; 1996 Aug; 19(4):305-13. PubMed ID: 8828993
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms.
    Cai J; Zhang W; Yi Z; Lu W; Wu Z; Chen J; Yu S; Fang Y; Zhang C
    Psychopharmacology (Berl); 2013 Nov; 230(1):49-55. PubMed ID: 23660601
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clozapine in patients with chronic schizophrenia: serum level, EEG and memory performance.
    Adler G; Grieshaber S; Faude V; Thebaldi B; Dressing H
    Pharmacopsychiatry; 2002 Sep; 35(5):190-4. PubMed ID: 12237790
    [TBL] [Abstract][Full Text] [Related]  

  • 57. More on obsessive-compulsive symptoms and clozapine.
    LaPorta LD
    J Clin Psychiatry; 1994 Jul; 55(7):312. PubMed ID: 8071293
    [No Abstract]   [Full Text] [Related]  

  • 58. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.
    Couchman L; Morgan PE; Spencer EP; Flanagan RJ
    Ther Drug Monit; 2010 Aug; 32(4):438-47. PubMed ID: 20463634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Integration of Clozapine-associated Harm Obsessions into Cognitive Behavioral Conceptualization and Treatment Planning for Thought Broadcasting: A Case Study.
    Kopelovich SL; Wood K; Cotes RO; Goldsmith DR
    J Psychiatr Pract; 2020 Jul; 26(4):329-336. PubMed ID: 32692132
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Toxic plasma concentration of clozapine in inflammatory processes].
    van Gool AR; de Jong MH; Verhoeven WM
    Tijdschr Psychiatr; 2010; 52(11):791-6. PubMed ID: 21064022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.